Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Upendra Parvathaneni

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
BMC Cancer|November 15, 2024
Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitorsCassie Pan, Kevin Ng, Jenna Voutsinas, et al.
Cancer Immunology Research|January 17, 2014
Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-IAude G Chapuis, Olga K Afanasiev, Jayasri G Iyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Journal of Palliative Medicine|December 1, 2021
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint InhibitorsCameron Chalker, Rafael Santana-Davila, Jenna M Voutsinas, et al.
Cancer Medicine|March 29, 2022
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patientsCameron Chalker, Jenna M Voutsinas, Qian Vicky Wu, et al.
Cancer Reports (Hoboken, N.J.)|February 5, 2025
Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal MelanomaJamie S K Takayesu, Upendra Parvathaneni, George E Laramore, et al.
Cancer|May 10, 2012
Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN)K Kian Ang, Amy Chen, Walter J Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialRenato G Martins, Upendra Parvathaneni, Julie E Bauman, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
Advances in Radiation Oncology|November 24, 2022
Evolutionary Action Score of <i>TP53</i> Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234Chieko Michikawa, Pedro A Torres-Saavedra, Natalie L Silver, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
BMC Cancer|November 15, 2024
Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitorsCassie Pan, Kevin Ng, Jenna Voutsinas, et al.
Cancer Immunology Research|January 17, 2014
Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-IAude G Chapuis, Olga K Afanasiev, Jayasri G Iyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Journal of Palliative Medicine|December 1, 2021
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint InhibitorsCameron Chalker, Rafael Santana-Davila, Jenna M Voutsinas, et al.
Cancer Medicine|March 29, 2022
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patientsCameron Chalker, Jenna M Voutsinas, Qian Vicky Wu, et al.
Cancer Reports (Hoboken, N.J.)|February 5, 2025
Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal MelanomaJamie S K Takayesu, Upendra Parvathaneni, George E Laramore, et al.
Cancer|May 10, 2012
Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN)K Kian Ang, Amy Chen, Walter J Curran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialRenato G Martins, Upendra Parvathaneni, Julie E Bauman, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
Advances in Radiation Oncology|November 24, 2022
Evolutionary Action Score of <i>TP53</i> Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234Chieko Michikawa, Pedro A Torres-Saavedra, Natalie L Silver, et al.
Pageof 9